Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LVRNA010 in Healthy Adults
NCT05599802Phase 1Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 1, open-label trial of LVRNA010 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoints: Incidence, severity, and duration of solicited adverse events at 7 days, Incidence, severity, and duration of unsolicited adverse events at 28 days and 1 more. Status: unknown.
02
Drugs
LVRNA010
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05599802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599802.